New Treatment Targets and Approaches for Hepatitis B Virus
Introduction: With the development of the direct acting antivirals aganist hepatitis C virus (HCV), the treatment of HCV has showed significiant progress. However, hepatitis B virus (HBV) therapy is still a topic of discussion. <p></p> Objectives: Because of that approved agents for HBV have some disadvantages including indefinite therapy, drug resistance, adverse effects and persistence of covalently closed circular deoxyribonucleic acid (cccDNA), there is a need for new treatment targets and approaches for HBV. And, there are several trials about this subject. New treatment targets for HBV consist revers transcription, immunoregulation, cccDNA formation and regulation, maturation and secretion of infectious virions and subviral particules, viral receptor, entry and cytosolic transport, nucleocapsid assembly. Therapeutic vaccination and traditional Chinese medicine are the other options for novel agents for HBV treatment. We summarised new treatment targets and approaches for HBV. <p></p> Conclusion: It is a certain fact that large-scale studies about all these molecules and approaches are required, in order to highlight the efficiency, drug interaction, safety and appropriate dose. <p></p>.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Anti-infective agents - 15(2017), 1, Seite 4-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Afyon, Murat [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC2000014577 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2000014577 | ||
| 003 | DE-627 | ||
| 005 | 20230516064851.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180127s2017 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a Paket_Artikel_Pharmazie_20180125.pp |
| 035 | |a (DE-627)OLC2000014577 | ||
| 035 | |a (DE-599)GBVOLC2000014577 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |
| 100 | 1 | |a Afyon, Murat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New Treatment Targets and Approaches for Hepatitis B Virus |
| 264 | 1 | |c 2017 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: With the development of the direct acting antivirals aganist hepatitis C virus (HCV), the treatment of HCV has showed significiant progress. However, hepatitis B virus (HBV) therapy is still a topic of discussion. <p></p> Objectives: Because of that approved agents for HBV have some disadvantages including indefinite therapy, drug resistance, adverse effects and persistence of covalently closed circular deoxyribonucleic acid (cccDNA), there is a need for new treatment targets and approaches for HBV. And, there are several trials about this subject. New treatment targets for HBV consist revers transcription, immunoregulation, cccDNA formation and regulation, maturation and secretion of infectious virions and subviral particules, viral receptor, entry and cytosolic transport, nucleocapsid assembly. Therapeutic vaccination and traditional Chinese medicine are the other options for novel agents for HBV treatment. We summarised new treatment targets and approaches for HBV. <p></p> Conclusion: It is a certain fact that large-scale studies about all these molecules and approaches are required, in order to highlight the efficiency, drug interaction, safety and appropriate dose. <p></p> | ||
| 700 | 1 | |a Artuk, Cumhur |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-infective agents |d Sharjah : Bentham Science, 2012 |g 15(2017), 1, Seite 4-8 |h Online-Ressource |w (DE-627)859772292 |w (DE-600)2856689-0 |w (DE-576)469947063 |x 2211-3533 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2017 |g number:1 |g pages:4-8 |
| 856 | 4 | 0 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=2211-3525&volume=15&issue=1&spage=4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_1200 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2017 |e 1 |h 4-8 | ||